Wolverine Asset Management LLC Buys New Stake in Ralliant Corporation $RAL

Wolverine Asset Management LLC purchased a new stake in shares of Ralliant Corporation (NYSE:RAL) during the third quarter, HoldingsChannel reports. The fund purchased 15,000 shares of the company’s stock, valued at approximately $656,000.

Other institutional investors have also bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Ralliant in the 3rd quarter worth $34,000. Arcadia Investment Management Corp MI lifted its holdings in shares of Ralliant by 119.2% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 2,576 shares of the company’s stock valued at $113,000 after acquiring an additional 1,401 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in Ralliant by 2.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 32,858 shares of the company’s stock worth $1,437,000 after acquiring an additional 779 shares in the last quarter. Meeder Asset Management Inc. increased its stake in Ralliant by 95,122.7% during the third quarter. Meeder Asset Management Inc. now owns 20,949 shares of the company’s stock worth $916,000 after acquiring an additional 20,927 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Ralliant during the third quarter worth approximately $69,000.

Ralliant Trading Down 0.7%

Shares of RAL opened at $53.51 on Friday. The company’s fifty day moving average is $50.12. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.49 and a quick ratio of 1.03. The stock has a market capitalization of $6.04 billion and a price-to-earnings ratio of 42.13. Ralliant Corporation has a 12-month low of $40.70 and a 12-month high of $55.08.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.02. The company had revenue of $529.10 million for the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Investors of record on Monday, December 8th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.4%. Ralliant’s dividend payout ratio is 15.75%.

Analyst Ratings Changes

Several research firms have recently issued reports on RAL. Barclays raised their price objective on Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, January 7th. Citigroup upgraded shares of Ralliant from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $53.00 to $61.00 in a research report on Monday, December 8th. Truist Financial began coverage on shares of Ralliant in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 target price for the company. Oppenheimer upped their price target on shares of Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Ralliant has an average rating of “Moderate Buy” and a consensus price target of $58.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.